NeuroOne Medical (NMTC) Letter to Stockholders

 NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on May 31, 2022. The letter may be accessed here.

The letter recaps the key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond directed at developing the Evo® platform thin film electrode technology for patients suffering from epilepsy, chronic back pain, and Parkinson's disease.

In his letter, Dave Rosa, Chief Executive Officer of NeuroOne, states, "As we continue to develop our platform thin film electrode technology, we remain confident it will represent a transformational tool for neurosurgeons and neurologists. …. I believe we are on the right path to creating a meaningful impact in patients' lives and have been encouraged by positive feedback from physicians and patients who are excited to see our products in the market."

Highlights from Fiscal Year 2021:

• Completed equity raise in the amount of $12.5M in January of 2021
• Uplisted to Nasdaq in May 2021
• Successful completion of feasibility testing of combination recording and ablation electrode
• Partnership with RBC Medical for development of hardware for NeuroOne's ablation electrode
• Initiated long term testing for a newly designed electrode family for treating chronic back pain due to failed back surgeries, Parkinson's disease, and epilepsy

Milestones for Fiscal Year 2022 and Beyond:

• Re-submission to FDA for <30 day use for sEEG product line expected in August 2022
• Complete research and development of ablation system, including the sEEG electrodes
• Continue development of electrode for chronic stimulation
• Build a world class management team
• Support Zimmer Biomet in future expected launch of sEEG electrode family
• Explore expanding new indications for chronic stimulation electrodes
• Continue to explore complementary technology and partnerships

https://www.streetinsider.com/Corporate+News/NeuroOne+Medical+%28NMTC%29+Issues+Letter+to+Stockholders/20165889.html